Could a pill stop the stomach bug? new vaccine trial shows promise
NCT ID NCT05212168
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested an experimental oral vaccine designed to protect against norovirus, a highly contagious virus that causes vomiting and diarrhea. Healthy adults aged 18 to 49 received either a single dose of the vaccine or a placebo. About a month later, all volunteers were intentionally exposed to the norovirus in a controlled setting to see if the vaccine could prevent illness. The trial measured how many people got sick and looked at immune responses in the blood.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- oral norovirus vaccine (VXA-G1.1-NN) with a double-stranded RNA adjuvant
- What this could lead to
- If successful, this could lead to a convenient single-dose oral vaccine that protects against norovirus, the leading cause of stomach flu outbreaks.
- What could go wrong
- This is an early-phase trial with only 165 participants, and it tested protection against one specific strain. The vaccine may not work as well in real-world settings or against other norovirus strains.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NOROVIRUS INFECTIONS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
AltaSciences LA
Cypress, California, 90630, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.